ArticleAmerican journal of nephrology2026
Immune Deposits, Complement Activation, and <italic>APOL1</italic> Risk Variants in Focal Segmental Glomerulosclerosis.
Article in American journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe role of immune deposits and complement activation in APOL1-mediated focal segmental glomerulosclerosis (FSGS) remains unclear. Using the CureGN cohort, we examined the associations between APOL1 renal risk variants (RRVs), glomerular immune deposits, and urinary complement activation.
methodsWe analyzed glomerular IgG, IgM, and C3 deposition, kidney biopsy findings, urinary membrane attack complex (sC5b9) levels, and clinical data in FSGS patients, regardless of race. Study participants were categorized as high-risk (two RRVs) or low-risk (zero to one RRV).
resultsOf 175 participants, 148 (84%) had genetic testing, among whom 31 were high-risk and 117 were low-risk participants. High-risk participants had a higher prevalence of collapsing FSGS (45% vs. 11%, p < 0.001) and mesangial IgG deposition (intensity >0) (32% vs. 3%, p < 0.001). Incident participants enrolled within 6 months of biopsy showed a trend toward higher urinary sC5b9-to-protein ratio in high-risk participants (0.15 [0.08-0.31] vs. 0.03 [0-0.20] μg/g, p = 0.09). IgG staining correlated with urinary sC5b9 levels (r = 0.34, p = 0.008), suggesting a link between IgG deposition and urinary membrane attack complex excretion.
conclusionsAPOL1 high-risk FSGS is associated with mesangial IgG deposition and increased urinary membrane attack complex levels, implicating immune-mediated mechanisms in FSGS pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.